Abmart
Custom monoclonal antibodies for pharmaceutical and research applications.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
CNY20.0m | Series B | ||
| Total Funding | 000k | ||
Abmart is a biotechnology company specializing in the development and production of monoclonal antibodies (mAbs) for research, diagnostics, and pharmaceutical applications. Founded in 2007 by Dr. Xun Meng and Dr. Changzheng Chen, the company operates primarily out of Shanghai, China. Dr. Meng, a biologist and entrepreneur, and Dr. Chen, a Stanford professor, aimed to industrialize and lower the cost of antibody production.
The company has developed a suite of proprietary technologies to streamline antibody discovery and production. These include SEAL™ (Surface Epitope Antibody Library) for creating diverse antibody libraries, PETAL™ for rapid mAb development within 30 days, and MabArray™, a high-capacity monoclonal antibody chip for proteome-scale screening and biomarker discovery. Abmart serves a global client base that includes academic researchers and major pharmaceutical companies. Its business model focuses on providing custom antibody services and products, aiming to make high-quality monoclonal antibodies more accessible and affordable. The company offers services for various stages of drug discovery, including target screening for CAR-T therapy and antibody-drug conjugates (ADCs).
Abmart's offerings are designed to support a wide range of applications, from basic protein research to the development of diagnostics and therapeutics for diseases like cancer. The company has established an industrialized production line for monoclonal antibodies and has received venture capital funding from investors including Northern Light Venture Capital. Its stated long-term goal is to create an "antibody democracy," enabling any researcher to obtain desired monoclonal antibodies affordably and efficiently.
Keywords: monoclonal antibodies, custom antibody, antibody discovery, biotechnology, proteome research, drug discovery, antibody production, biomarker discovery, MabArray, SEAL technology, PETAL technology, CAR-T target screening, ADC development, pharmaceutical services, protein research, diagnostics, therapeutics, Abmart, contract research organization, life sciences